Will This Analyst Downgrade Hurt Theravance (THRX) Stock Today?

NEW YORK (TheStreet) -- Robert W. Baird downgraded Theravance  (THRX) to "neutral" from "outperform" and set a $21 price target. The firm noted Breo sales have been disappointing.

The stock was down 3.53% to $27.64 at 9:31 a.m. on Monday.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

THRX Chart

THRX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await

Alphabet Earnings and 4 Other Business Stories You Must Know Monday Morning

Alphabet Earnings and 4 Other Business Stories You Must Know Monday Morning

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Global Stocks Slip as 3% 10-Year Yields, Bad Tech News Unsettle Markets

Global Stocks Slip as 3% 10-Year Yields, Bad Tech News Unsettle Markets